N ot much progress has occurred in guidelines to treat blood pressure (BP) during acute stroke since Sir George Pickering wrote in 1968 about cerebral hemorrhage: "Probably diastolic pressures over 110 are worth reducing to 90 mm Hg. This is a guess, and theoretical arguments could be urged against, or for, different figures," and about ischemic stroke: "There is no evidence that reducing arterial pressure in the acute phase will help." 1 Perhaps the different purposes of treating BP for the prevention of stroke versus managing BP during its acute phase explain this. In the former, BP reduction (and blockade of vasoactive systems) aims at reducing arteriolar remodeling and arterial atherosclerosis, the culprits for both intracerebral hemorrhage (ICH) and ischemic strokes. Its effectiveness has been unequivocally proven; stroke prevention is quantitatively the most beneficial effect of antihypertensive therapy. In contrast, the purpose of managing BP during an acute stroke is to improve outcomes by diminishing the magnitude of the bleed, or the development of edema in the ischemic region, or the extension of tissue necrosis into the penumbra. The physiology of the hypertensive cerebral circulation, before and during a stroke, is complex and contributes to the fact that achieving one of the goals above may conflict with achieving another one.
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Normal autoregulation of cerebral blood flow (CBF) maintains it constant over a wide range of mean arterial pressures (MAPs; Ϸ50 through Ϸ150 mm Hg; Figure A) . BPs above these limits will produce cerebral edema. In contrast, below the lower limit (located at Ϸ75% of usual MAP), hypoperfusion does not cause immediate ischemia, because the brain is capable of increasing O 2 extraction (thick portion of the curve in the Figure) . Cerebral hypoxemia ensues if additional hypotension overwhelms this compensation.
In chronic hypertension, autoregulation is shifted to the right ( Figure B) . Hence, patients are somewhat protected from developing cerebral edema (ie, hypertensive encephalopathy is more likely with abrupt BP elevation in a previously normotensive individual, eg, acute glomerulonephritis in children or eclampsia, than in severe chronic hypertension). In contrast, hypertensive subjects have an increased risk of cerebral hypoperfusion with abrupt BP reduction, because the lower limit of autoregulation is also right-shifted.
Knowing the range of autoregulation in a patient with an acute stroke would permit safe targeting of BP reduction, avoiding cerebral hypoperfusion or hyperperfusion. However, this is not possible, because during an acute stroke BP is higher, by an unknown amount, than that preceding the event ( Figure C) . This pressor effect of stroke is present in 80% of patients and abates over 7 to 10 days. It could be argued that in a hypertensive ischemic stroke, the risk of cerebral edema is less than that of hypoperfusion because of the preceding right-shifted autoregulation, even without knowing its magnitude. Current guidelines match this speculation, because no therapy is recommended unless BP exceeds 220/120 mm Hg in uncomplicated ischemic stroke. 2 However, the situation is compounded by disrupted autoregulation in the penumbra and ischemic brain ( Figure D) , where CBF is directly dependent on BP; hence, any BP elevation increases risk of further bleed or cerebral edema, whereas any BP reduction threatens hypoperfusion and extension of the stroke to the area of the penumbra.
In ischemic stroke, several recent studies suggest that current guidelines may underestimate detrimental effects of untreated hypertension and overestimate risk of BP reduction. In a study of 2178 ischemic strokes in Mongolia, the relationship among BP (9.3 hours from event onset), multiple outcomes, and disability was not statistically significant, as it was for 1760 ICHs. However, systolic BP (SBP) Ͼ200 mm Hg, that is, 20 mm Hg lower than the current target for treatment, had an odds ratio of 4.36 for adjusted mortality. 3 In Tinzaparin in Acute Ischemic Stroke, BP of 1479 patients (24 to 48 hours after onset) was a major determinant of early recurrence and death or dependency at 6 months, despite the fact that subjects with BP Ͼ220/120 mm Hg were excluded. 4 In 1722 placebo participants of Virtual International Stroke Trials Archive (enrolled 1.0 to 7.9 hours after the event), odds ratios for neurological impairment at 7 days and functional outcomes at 90 days related to higher SBP at entry, smaller reductions of SBP over the initial 24 hours, and SBP at 24 hours, although Ͼ75 mm Hg SBP reduction was associated with worse outcomes. 5 In the Thrombolysis in Cardiac Arrest Trial (1092 patients recruited within 24 hours of event onset), the relationship between SBP and disability at 3 months was U-shaped, with both SBP Ն181 (odds ratio: 2.2) and Ͻ136 mm Hg carrying worse prognosis. Best outcomes were observed with 8-hour SBP reduction of 10.0 to 27.2 mm Hg, although the benefit was not observed in subjects older than 76 years. Greater SBP reductions were detrimental, particularly in the elderly and more so if obtained with antihypertensive therapy. Authors suggested that BP targets currently used for tissue plasminogen activator administration (Ͻ185/110 mm Hg) could be beneficially extended to all patients within the first 24 hours, if sharp BP reduction is avoided and age is taken into consideration. 6 Clinical trials favoring intervention at lower BP levels are consistent with a meta-analysis of the effect of 5 families of antihypertensive drugs on CBF. When given to 291 patients in 11 trials, 0.5 to 7.0 days after event onset, MAP reductions of Ϫ6.0 to Ϫ15.7 mm Hg did not reduce CBF. 7 Most measurements (single photon emission computed tomography, Xenon-computed tomography, and positron emission tomography-computed tomography) were of hemispheric CBF, but reports on penumbra CBF produced similar results.
Furthermore, unwarranted withholding of treatment may neglect BP-independent beneficial effects of certain drugs. In the Acute Candesartan Cilexetil Therapy in Stroke Survivors Trial (nϭ339), candesartan administration within 24 to 36 hours of event onset reduced 12-month mortality and cardiovascular events by more than half, without BP reduction beyond that by placebo over 7 days. 8 Benefit was in cardiovascular morbidity/mortality, not in recurrent strokes, leading to the speculation that early protection of cerebral autonomic function may be important for future protection of cardiovascular disease.
In a metaregression analysis of 37 trials, including 9008 patients with ischemic stroke or ICH, the relationship among on-treatment BP (active versus control groups), early (Ͻ1 month) and late (90 day) mortalities, and 90-day death/ dependency was U-shaped. 9 Treatment, given within 1 week, involved 13 classes of drugs. Lowest odds ratios for untoward outcomes were obtained with ⌬SBPs of Ϫ8.1 to Ϫ14.6 mm Hg. The Controlling Hypertension and Hypotension Immediately Post-Stroke pilot study (nϭ179) directly tested the effect of lisinopril or labetalol therapy on ischemic stroke and ICH within 36 hours of onset. Target SBP was 145 to 155 mm Hg, to be achieved within 8 hours, with discontinuation if Ͻ140 mm Hg. There were no differences between treatments and placebo in combined death/dependency at 2 weeks. 10 However, active therapy halved mortality at 3 months (9.7% versus 20.3%). Despite greater SBP reduction with active therapy (Ϫ21 mm Hg versus placebo Ϫ11 mm Hg), sustained over 2 weeks, neither deterioration of neurological status over the initial 72 hours nor any increase in serious adverse events was observed.
In this issue of Hypertension, 11 investigators of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial present further analyses of their data, the first attempt at exploring target BP for patients with acute ICH. They previously published a 24-hour 22.6% smaller proportional growth of hematoma size (CT scan) by aggressive therapy with goal SBP Ͻ140 mm Hg (achieved in 1 hour in 42% and in 6 hours in 66% of 203 patients), compared with usual care (1999 American Heart Association guidelines, SBP Ͻ180 mm Hg, nϭ201). 12 Patients with compelling indications or contraindications for hypertension treatment, structural cerebral abnormalities, deep coma, and requiring tissue plasminogen activator or neurosurgical intervention were excluded. Participants were randomized Ϸ3.5 hours and started therapy Ϸ4.2 hours after event onset. They were mostly Chinese (95%) and hypertensive (74%), with average BP 181/103 mm Hg (74% required therapy in the usual care versus 98% in the intensive group). SBP throughout the initial 24 hours was 10.8 mm Hg lower in the intensive group. The risk of substantial hematoma growth (defined as Ͼ33% or Ͼ12.5 mL) was 36% less in the intensive group (26% versus 40%), independent of age (Ͼ or Ͻ65), SBP (Ͼ or Ͻ181), or functional status (National Institutes of Health Stroke Scale Ͼ or Ͻ9). The effect was larger in subjects randomized within 4 hours of onset (nϭ210, ⌬Ϫ52%, intensive: 15% versus usual care: 30%). Early (72-hour) neurological deterioration, 90-day death/dependency, and serious adverse events were not different between groups. In the current publication, the most important observation is that achieved SBP throughout 24 hours (not baseline BP) is the major determinant of hematoma growth at 24 hours, in single and multivariate regression analyses and in covariate adjusted analysis of trends for tertiles of achieved SBP. Based on observed maximum benefit in the lowest tertile (median: 135 mm Hg), the authors cautiously suggest that achieving SBP 130 to 140 mm Hg over the initial 24 hours may be the target of treatment in ICH. Actually, their Figure 3 shows Ϸ20 patients with SBP Ͻ130 mm Hg (although this was the limit to stop therapy), without any evidence for a J-curve, will provide additional data. The recently published guidelines from the American Heart Association and American Stroke Association acknowledge that, in ICH, intensive BP lowering is clinically feasible and potentially safe, although target BP and duration of therapy remain unclear. 13 However, the flurry of research results over the last 2 years already suggests that our current guidelines are too permissive, perhaps even harmful, and will have to be revised soon, recommending judicious BP reduction to lower targets in ischemic stroke and a more aggressive antihypertensive approach to acute ICH.
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